China Approves First Recombinant Botulinum Toxin for Glabellar Lines
The neurotoxin, developed by Claruvis Pharmaceutical, uses a precision-engineered recombinant manufacturing process for botulinum toxin type A.
The neurotoxin, developed by Claruvis Pharmaceutical, uses a precision-engineered recombinant manufacturing process for botulinum toxin type A.
A study found increases in collagen, elastin, and other extracellular matrix proteins following Radiesse treatment, along with improvements in markers of solar elastosis, a sign of sun-damaged skin.